Discovery of novel GPVI receptor antagonists by structure-based repurposing.

Discovery of novel GPVI receptor antagonists by structure-based repurposing.

Inappropriate platelet aggregation creates a cardiovascular risk that is largely managed with thienopyridines and aspirin. Although effective, these drugs carry risks of increased bleeding and drug 'resistance', underpinning a drive for new antiplatelet agents. To discover such drugs, one...

Full description

Bibliographic Details
Main Authors: Lewis Taylor, Sridhar R Vasudevan, Chris I Jones, Jonathan M Gibbins, Grant C Churchill, R Duncan Campbell, Carmen H Coxon
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4074120?pdf=render

Internet

http://europepmc.org/articles/PMC4074120?pdf=render

Similar Items